ANI Pharmaceuticals ANIP Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $883.37M+43.8% | $614.38M+26.2% | $486.82M+53.9% | $316.39M+46.4% | ||
| $341.31M+36.4% | $250.21M+37.8% | $181.51M+30.8% | $138.79M+37.9% | ||
| $542.06M+48.8% | $364.17M+19.3% | $305.3M+71.9% | $177.6M+53.7% | ||
| 61.4%+2.1pp | 59.3%-3.4pp | 62.7%+6.6pp | 56.1%+2.7pp | ||
| $51.66M+15.9% | $44.58M+30.0% | $34.29M+53.6% | $22.32M+96.3% | ||
| $317.75M+27.3% | $249.64M+54.4% | $161.7M+30.4% | $124.04M+47.2% | ||
| $772.27M+25.8% | $613.79M+39.5% | $439.85M+25.1% | $351.67M+37.4% | ||
| $111.09M— | —— | $46.97M+227% | -$37.1M+6.8% | ||
| 12.6%— | —— | 9.6%+21.4pp | -11.7%+6.7pp | ||
| -$20.06M-14.0% | -$17.6M+34.7% | -$26.94M+4.0% | -$28.05M-135% | ||
| $1.93M+148% | -$4.03M-2,436% | -$159K-122% | $712K+116% | ||
| $95.79M+531% | -$22.21M-212% | $19.87M+132% | -$62.67M-11.8% | ||
| $17.45M+573% | -$3.69M— | —— | -$14.77M-9.8% | ||
| $78.34M+523% | -$18.52M-199% | $18.78M+139% | -$47.9M-12.4% | ||
| 8.9%+11.9pp | -3%-6.9pp | 3.9%+19.0pp | -15.1%+4.6pp | ||
| $3.35+394% | -$1.14-239% | $0.82+127% | -$3.05+10.3% | ||
| $202.51M+283% | $52.92M-50.4% | $106.76M+437% | $19.87M+166% | ||
| 22.9%+14.3pp | 8.6%-13.3pp | 21.9%+15.7pp | 6.3%+2.8pp | ||
| $111.09M+850% | -$14.82M-132% | $46.97M+227% | -$37.1M+6.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.